Ming Hu

List of Publications by Year in Descending Order

238 papers	6,470 citations	46 h-index	67 g-index
252 ext. papers	7,156 ext. citations	4.5 avg, IF	5.85 L-index

#	Paper	IF	Citations
238	Development of Rofecoxib-Based Fluorophores from ACQ to AIE by Positional Regioisomerization.. *ChemPlusChem*, **2022**, e202100522	2.8	0
237	Intestinal Excretion, Intestinal Recirculation, and Renal Tubule Reabsorption Are Underappreciated Mechanisms That Drive the Distribution and Pharmacokinetic Behavior of Small Molecule Drugs. *Journal of Medicinal Chemistry*, **2021**, 64, 7045-7059	8.3	4
236	Age-and Region-Dependent Disposition of Raloxifene in Rats. *Pharmaceutical Research*, **2021**, 38, 1357-1367	4.5	
235	The Function of Multidrug Resistance-associated Protein 3 in the Transport of Bile Acids under Normal Physiological and Lithocholic Acid-induced Cholestasis Conditions. *Current Drug Metabolism* , **2021**, 22, 353-362	3.5	0
234	Parallel guidewire technique in acute ischemic stroke secondary to carotid artery dissection. *Annals of Palliative Medicine*, **2021**, 10, 266-277	1.7	
233	Meet Our Editor-in-Chief. *Current Drug Metabolism*, **2021**, 22, 1-1	3.5	
232	One-Step Transformation from Rofecoxib to a COX-2 NIR Probe for Human Cancer Tissue/Organoid Targeted Bioimaging.. *ACS Applied Bio Materials*, **2021**, 4, 2723-2731	4.1	6
231	Glucuronides Hydrolysis by Intestinal Microbial -Glucuronidases (GUS) Is Affected by Sampling, Enzyme Preparation, Buffer pH, and Species. *Pharmaceutics*, **2021**, 13,	6.4	1
230	A positive-negative switching LC-MS/MS method for quantification of fenoldopam and its phase II metabolites: Applications to a pharmacokinetic study in rats. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2021**, 1179, 122854	3.2	
229	Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer. *Journal of Natural Products*, **2021**, 84, 2486-2495	4.9	1
228	UGT1A1 dysfunction increases liver burden and aggravates hepatocyte damage caused by long-term bilirubin metabolism disorder. *Biochemical Pharmacology*, **2021**, 190, 114592	6	3
227	Development of Rofecoxib-Based Fluorescent Probes and Investigations on Their Solvatochromism, AIE Activity, Mechanochromism, and COX-2-Targeted Bioimaging. *Analytical Chemistry*, **2021**, 93, 11991-12000	7.8	3
226	Disordered farnesoid X receptor signaling is associated with liver carcinogenesis in Abcb11-deficient mice. *Journal of Pathology*, **2021**, 255, 412-424	9.4	2
225	Pharmacokinetic and Metabolic Profiling of Key Active Components of Dietary Supplement Extract for Prevention against Oral Carcinoma. *Journal of Agricultural and Food Chemistry*, **2020**, 68, 6576-6587	5.7	3
224	Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold. *European Journal of Medicinal Chemistry*, **2020**, 200, 112417	6.8	4
223	Irinotecan-mediated diarrhea is mainly correlated with intestinal exposure to SN-38: Critical role of gut Ugt. *Toxicology and Applied Pharmacology*, **2020**, 398, 115032	4.6	5
222	Flavonoids interference in common protein assays: Effect of position and degree of hydroxyl substitution. *Analytical Biochemistry*, **2020**, 597, 113644	3.1	1

221	A novel strategy for screening bioavailable quality markers of traditional Chinese medicine by integrating intestinal absorption and network pharmacology: Application to Wu Ji Bai Feng Pill. *Phytomedicine*, **2020**, 76, 153226	6.5	3
220	Insight into tartrate inhibition patterns in vitro and in vivo based on cocrystal structure with UDP-glucuronosyltransferase 2B15. *Biochemical Pharmacology*, **2020**, 172, 113753	6	5
219	Acute changes in colonic PGE levels as a biomarker of efficacy after treatment of the Pirc (F344/NTac-Apc) rat with celecoxib. *Inflammation Research*, **2020**, 69, 131-137	7.2	2
218	Development and validation of ultra-high-performance liquid chromatography-mass spectrometry method for the determination of raloxifene and its phase II metabolites in plasma: Application to pharmacokinetic studies in rats. *Journal of Separation Science*, **2020**, 43, 4414-4423	3.4	2
217	Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity. *Expert Opinion on Drug Metabolism and Toxicology*, **2020**, 16, 1109-1124	5.5	10
216	Rapid intestinal glucuronidation and hepatic glucuronide recycling contributes significantly to the enterohepatic circulation of icaritin and its glucuronides in vivo. *Archives of Toxicology*, **2020**, 94, 3737-3749	5.8	5
215	Design and Synthesis of a Novel NIR Celecoxib-Based Fluorescent Probe for Cyclooxygenase-2 Targeted Bioimaging in Tumor Cells. *Molecules*, **2020**, 25,	4.8	4
214	Development and validation of an LC-MS/MS method for the quantification of flavonoid glucuronides (wogonoside, baicalin, and apigenin-glucuronide) in the bile and blood samples: Application to a portal vein infusion study. *Analytical Biochemistry*, **2020**, 601, 113723	3.1	4
213	Chronic Alcohol Consumption Increased Bile Acid Levels in Enterohepatic Circulation and Reduced Efficacy of Irinotecan. *Alcohol and Alcoholism*, **2020**, 55, 264-277	3.5	8
212	Magnolia extract is effective for the chemoprevention of oral cancer through its ability to inhibit mitochondrial respiration at complex I. *Cell Communication and Signaling*, **2020**, 18, 58	7.5	8
211	Metabolic profiles of Xiao Chai Hu Tang in mouse plasma, bile and urine by the UHPLC-ESI-Q-TOF/MS technique. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2019**, 1128, 121767	3.2	6
210	Potential of herb-drug / herb interactions between substrates and inhibitors of UGTs derived from herbal medicines. *Pharmacological Research*, **2019**, 150, 104510	10.2	15
209	Xiao-Chai-Hu-Tang (XCHT) Intervening Irinotecan's Disposition: The Potential of XCHT in Alleviating Irinotecan-Induced Diarrhea. *Current Cancer Drug Targets*, **2019**, 19, 551-560	2.8	3
208	An update on polyphenol disposition via coupled metabolic pathways. *Expert Opinion on Drug Metabolism and Toxicology*, **2019**, 15, 151-165	5.5	10
207	Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Determine the Disposition of Esculetin-7-O-Glucuronide and 4-Methylesculetin-7-O-Glucuronide. *Drug Metabolism and Disposition* , **2019**, 47, 203-214	4	1
206	Bioavailability and Pharmacokinetics of Dihydroartemisinin (DHA) and its Analogs: Mechanistic Studies on its ADME. *Current Pharmacology Reports*, **2018**, 4, 33-44	5.5	1
205	Tissue Distribution and Gender-Specific Protein Expression of Cytochrome P450 in five Mouse Genotypes with a Background of FVB. *Pharmaceutical Research*, **2018**, 35, 114	4.5	8
204	Development and validation of a sensitive LC-MS/MS method for simultaneous determination of eight tyrosine kinase inhibitors and its application in mice pharmacokinetic studies. *Journal of Pharmaceutical and Biomedical Analysis*, **2018**, 148, 65-72	3.5	15

203	Vitexin protects dopaminergic neurons in MPTP-induced Parkinson's disease through PI3K/Akt signaling pathway. *Drug Design, Development and Therapy*, **2018**, 12, 565-573	4.4	45
202	Age-related changes in hepatic expression and activity of drug metabolizing enzymes in male wild-type and breast cancer resistance protein knockout mice. *Biopharmaceutics and Drug Disposition*, **2018**, 39, 344-353	1.7	3
201	Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis. *Journal of Controlled Release*, **2018**, 286, 315-325	11.7	48
200	Impact of diet on irinotecan toxicity in mice. *Chemico-Biological Interactions*, **2018**, 291, 87-94	5	8
199	Simultaneous determination of tilianin and its metabolites in mice using ultra-high-performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetic study. *Biomedical Chromatography*, **2018**, 32, e4139	1.7	5
198	Accurate quantification of PGE in the polyposis in rat colon (Pirc) model by surrogate analyte-based UPLC-MS/MS. *Journal of Pharmaceutical and Biomedical Analysis*, **2018**, 148, 42-50	3.5	6
197	Interplay of Efflux Transporters with Glucuronidation and Its Impact on Subcellular Aglycone and Glucuronide Disposition: A Case Study with Kaempferol. *Molecular Pharmaceutics*, **2018**, 15, 5602-5614	5.6	2
196	Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy. *Cancer Research*, **2018**, 78, 5656-5667	10.1	28
195	Metabolism of Phenolic Compounds in LPS-stimulated Raw264.7 Cells Can Impact Their Anti-inflammatory efficacy: Indication of Hesperetin. *Journal of Agricultural and Food Chemistry*, **2018**, 66, 6042-6052	5.7	10
194	Transport-Glucuronidation Classification System and PBPK Modeling: New Approach To Predict the Impact of Transporters on Disposition of Glucuronides. *Molecular Pharmaceutics*, **2017**, 14, 2884-2898	5.6	7
193	Glucuronidation: driving factors and their impact on glucuronide disposition. *Drug Metabolism Reviews*, **2017**, 49, 105-138	7	41
192	Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Regulate the Disposition of Acacetin Glucuronides. *Pharmaceutical Research*, **2017**, 34, 1402-1415	4.5	8
191	Sulfotransferases and Breast Cancer Resistance Protein Determine the Disposition of Calycosin in Vitro and in Vivo. *Molecular Pharmaceutics*, **2017**, 14, 2917-2929	5.6	8
190	LC-MS/MS quantification of sulfotransferases is better than conventional immunogenic methods in determining human liver SULT activities: implication in precision medicine. *Scientific Reports*, **2017**, 7, 3858	4.9	14
189	Development of a validated UPLC-MS/MS method for determination of humantenmine in rat plasma and its application in pharmacokinetics and bioavailability studies. *Biomedical Chromatography*, **2017**, 31, e4017	1.7	12
188	Inhibition of Human UGT1A1-Mediated Bilirubin Glucuronidation by Polyphenolic Acids Impact Safety of Popular Salvianolic Acid A/B-Containing Drugs and Herbal Products. *Molecular Pharmaceutics*, **2017**, 14, 2952-2966	5.6	10
187	High-Throughput and Reliable Isotope Label-free Approach for Profiling 24 Metabolic Enzymes in FVB Mice and Sex Differences. *Drug Metabolism and Disposition*, **2017**, 45, 624-634	4	6
186	Metabolic Disposition of Luteolin Is Mediated by the Interplay of UDP-Glucuronosyltransferases and Catechol-O-Methyltransferases in Rats. *Drug Metabolism and Disposition*, **2017**, 45, 306-315	4	25

185	Disposition of Flavonoids for Personal Intake. *Current Pharmacology Reports*, **2017**, 3, 196-212	5.5	4
184	An LC-MS/MS method for simultaneous determination of nine steroidal saponins from Paris polyphylla var. in rat plasma and its application to pharmacokinetic study. *Journal of Pharmaceutical and Biomedical Analysis*, **2017**, 145, 675-681	3.5	11
183	An UPLC-MS/MS method for quantifying tetrandrine and its metabolite berbamine in human blood: Application to a human pharmacokinetic study. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2017**, 1070, 92-96	3.2	10
182	Profiles and Gender-Specifics of UDP-Glucuronosyltransferases and Sulfotransferases Expressions in the Major Metabolic Organs of Wild-Type and Efflux Transporter Knockout FVB Mice. *Molecular Pharmaceutics*, **2017**, 14, 2967-2976	5.6	4
181	Challenges and Opportunities with Predicting in Vivo Phase II Metabolism via Glucuronidation from in Vitro Data. *Current Pharmacology Reports*, **2016**, 2, 326-338	5.5	23
180	In□vitro glucuronidation of methyl gallate and pentagalloyl glucopyranose by liver microsomes. *Drug Metabolism and Pharmacokinetics*, **2016**, 31, 292-303	2.2	4
179	Novel histone deacetylase inhibitors derived from Magnolia officinalis significantly enhance TRAIL-induced apoptosis in non-small cell lung cancer. *Pharmacological Research*, **2016**, 111, 113-125	10.2	23
178	Development and validation of an UPLC-MS/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: Application to a pharmacokinetic study of irinotecan in rats. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2016**, 1015-1016, 34-41	3.2	21
177	Curcumin Affects Phase II Disposition of Resveratrol Through Inhibiting Efflux Transporters MRP2 and BCRP. *Pharmaceutical Research*, **2016**, 33, 590-602	4.5	28
176	SGLT-1 Transport and Deglycosylation inside Intestinal Cells Are Key Steps in the Absorption and Disposition of Calycosin-7-O-□-D-Glucoside in Rats. *Drug Metabolism and Disposition*, **2016**, 44, 283-96	4	18
175	Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/□catenin signaling. *Oncotarget*, **2016**, 7, 31413-28	3.3	76
174	In Vivo Exposure of Kaempferol Is Driven by Phase II Metabolic Enzymes and Efflux Transporters. *AAPS Journal*, **2016**, 18, 1289-1299	3.7	26
173	Establishment and use of new MDCK II cells overexpressing both UGT1A1 and MRP2 to characterize flavonoid metabolism via the glucuronidation pathway. *Molecular Nutrition and Food Research*, **2016**, 60, 1967-83	5.9	9
172	Disposition of flavonoids via recycling: Direct biliary excretion of enterically or extrahepatically derived flavonoid glucuronides. *Molecular Nutrition and Food Research*, **2016**, 60, 1006-19	5.9	29
171	Characterization of oxygenated metabolites of ginsenoside Rg1 in plasma and urine of rat. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2016**, 1026, 75-86	3.2	9
170	Determination of 7□OH cholesterol by LC-MS/MS: Application in assessing the activity of CYP7A1 in cholestatic minipigs. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2016**, 1025, 76-82	3.2	7
169	Development and validation of an UPLC-MS/MS method for the quantification of ethoxzolamide in blood, brain tissue, and bioequivalent buffers: applications to absorption, brain distribution, and pharmacokinetic studies. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2015**, 986-987, 54-9	3.2	3
168	Quantitation of celecoxib and four of its metabolites in rat blood by UPLC-MS/MS clarifies their blood distribution patterns and provides more accurate pharmacokinetics profiles. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2015**, 1001, 202-11	3.2	12

167	Developing an activity and absorption-based quality control platform for Chinese traditional medicine: Application to Zeng-Sheng-Ping(Antitumor B). *Journal of Ethnopharmacology*, **2015**, 172, 195-201	5	13
166	Determination of pharmacokinetics of chrysin and its conjugates in wild-type FVB and Bcrp1 knockout mice using a validated LC-MS/MS method. *Journal of Agricultural and Food Chemistry*, **2015**, 63, 2902-10	5.7	35
165	UDP-Glucuronosyltransferases 1A6 and 1A9 are the Major Isozymes Responsible for the 7-O-Glucuronidation of Esculetin and 4-Methylesculetin in Human Liver Microsomes. *Drug Metabolism and Disposition*, **2015**, 43, 977-83	4	10
164	A combined strategy of mass fragmentation, post-column cobalt complexation and shift in ultraviolet absorption spectra to determine the uridine 5'-diphospho-glucuronosyltransferase metabolism profiling of flavones after oral administration of a flavone mixture in rats. *Journal of Chromatography A*, **2015**, 1395, 116-28	4.5	26
163	Triple Recycling Processes Impact Systemic and Local Bioavailability of Orally Administered Flavonoids. *AAPS Journal*, **2015**, 17, 723-36	3.7	32
162	Simultaneous determinations of 17 marker compounds in Xiao-Chai-Hu-Tang by LC-MS/MS: Application to its pharmacokinetic studies in mice. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2015**, 1003, 12-21	3.2	15
161	Severely Impaired and Dysregulated Cytochrome P450 Expression and Activities in Hepatocellular Carcinoma: Implications for Personalized Treatment in Patients. *Molecular Cancer Therapeutics*, **2015**, 14, 2874-86	6.1	43
160	Development and validation of an UPLC-MS/MS method for the quantification of columbin in biological matrices: Applications to absorption, metabolism, and pharmacokinetic studies. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2015**, 1002, 13-8	3.2	1
159	Species- and gender-dependent differences in the glucuronidation of a flavonoid glucoside and its aglycone determined using expressed UGT enzymes and microsomes. *Biopharmaceutics and Drug Disposition*, **2015**, 36, 622-35	1.7	20
158	Factors Influencing Oral Bioavailability of Thai Mango Seed Kernel Extract and Its Key Phenolic Principles. *Molecules*, **2015**, 20, 21254-73	4.8	25
157	Reductive metabolism of oxymatrine is catalyzed by microsomal CYP3A4. *Drug Design, Development and Therapy*, **2015**, 9, 5771-83	4.4	12
156	Characterization of oxygenated metabolites of ginsenoside Rb1 in plasma and urine of rat. *Journal of Agricultural and Food Chemistry*, **2015**, 63, 2689-700	5.7	11
155	Significantly decreased and more variable expression of major CYPs and UGTs in liver microsomes prepared from HBV-positive human hepatocellular carcinoma and matched pericarcinomatous tissues determined using an isotope label-free UPLC-MS/MS method. *Pharmaceutical Research*, **2015**, 32, 1141-57	4.5	32
154	A validated liquid chromatography-tandem mass spectrometry method for the determination of methyl gallate and pentagalloyl glucopyranose: application to pharmacokinetic studies. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2015**, 986-987, 12-7	3.2	15
153	Uptake of polymyxin B into renal cells. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 4200-2	5.9	40
152	Amino acid facilitates absorption of copper in the Caco-2 cell culture model. *Life Sciences*, **2014**, 109, 50-6	6.8	25
151	Absolute quantification of UGT1A1 in various tissues and cell lines using isotope label-free UPLC-MS/MS method determines its turnover number and correlates with its glucuronidation activities. *Journal of Pharmaceutical and Biomedical Analysis*, **2014**, 88, 180-90	3.5	17
150	Breast cancer resistance protein-mediated efflux of luteolin glucuronides in HeLa cells overexpressing UDP-glucuronosyltransferase 1A9. *Pharmaceutical Research*, **2014**, 31, 847-60	4.5	20

149	Transformation of ginsenosides from notoginseng by artificial gastric juice can increase cytotoxicity toward cancer cells. *Journal of Agricultural and Food Chemistry*, **2014**, 62, 2558-73	5.7	40
148	In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 2740-6	5.9	122
147	Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 1603-14	5.9	44
146	Disposition of flavonoids impacts their efficacy and safety. *Current Drug Metabolism*, **2014**, 15, 841-64	3.5	31
145	The influences of aconitine, an active/toxic alkaloid from aconitum, on the oral pharmacokinetics of CYP3A probe drug buspirone in rats. *Drug Metabolism Letters*, **2014**, 8, 135-44	2.1	4
144	Chemopreventive effect of a mixture of Chinese Herbs (antitumor B) on chemically induced oral carcinogenesis. *Molecular Carcinogenesis*, **2013**, 52, 49-56	5	17
143	Bioactivity and bioavailability of ginsenosides are dependent on the glycosidase activities of the A/J mouse intestinal microbiome defined by pyrosequencing. *Pharmaceutical Research*, **2013**, 30, 836-46	4.5	40
142	Validated LC-MS/MS method for the determination of 3-hydroxflavone and its glucuronide in blood and bioequivalent buffers: application to pharmacokinetic, absorption, and metabolism studies. *Journal of Pharmaceutical and Biomedical Analysis*, **2013**, 85, 245-52	3.5	4
141	Gender-dependent differences in uridine 5'-diphospho-glucuronosyltransferase have implications in metabolism and clearance of xenobiotics. *Expert Opinion on Drug Metabolism and Toxicology*, **2013**, 9, 1555-69	5.5	9
140	The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone. *Food and Chemical Toxicology*, **2013**, 51, 396-403	4.7	20
139	Revolving door action of breast cancer resistance protein (BCRP) facilitates or controls the efflux of flavone glucuronides from UGT1A9-overexpressing HeLa cells. *Molecular Pharmaceutics*, **2013**, 10, 1736-50	5.6	19
138	The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells. *Toxicology Letters*, **2013**, 216, 86-99	4.4	59
137	Mutual regioselective inhibition of human UGT1A1-mediated glucuronidation of four flavonoids. *Molecular Pharmaceutics*, **2013**, 10, 2891-903	5.6	11
136	In vitro pharmacodynamics of AZD5206 against Staphylococcus aureus. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 1062-4	5.9	5
135	A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 1104-10	5.1	30
134	Quantitative prediction of glucuronidation in humans using the in vitro- in vivo extrapolation approach. *Current Topics in Medicinal Chemistry*, **2013**, 13, 1343-52	3	29
133	A novel local recycling mechanism that enhances enteric bioavailability of flavonoids and prolongs their residence time in the gut. *Molecular Pharmaceutics*, **2012**, 9, 3246-58	5.6	28
132	A new strategy to rapidly evaluate kinetics of glucuronide efflux by breast cancer resistance protein (BCRP/ABCG2). *Pharmaceutical Research*, **2012**, 29, 3199-208	4.5	13

131	Mutual interactions between flavonoids and enzymatic and transporter elements responsible for flavonoid disposition via phase II metabolic pathways. *RSC Advances*, **2012**, 2, 7948-7963	3.7	49
130	Development and validation of a highly sensitive UPLC-MS/MS method for simultaneous determination of aconitine, mesaconitine, hypaconitine, and five of their metabolites in rat blood and its application to a pharmacokinetics study of aconitine, mesaconitine, and hypaconitine. *Xenobiotica*, **2012**, 42, 518-25	2	18
129	Effects of estrogen and estrus cycle on pharmacokinetics, absorption, and disposition of genistein in female Sprague-Dawley rats. *Journal of Agricultural and Food Chemistry*, **2012**, 60, 7949-56	5.7	10
128	SULT1A3-mediated regiospecific 7-O-sulfation of flavonoids in Caco-2 cells can be explained by the relevant molecular docking studies. *Molecular Pharmaceutics*, **2012**, 9, 862-73	5.6	21
127	Response to Comment on Uridine Diphosphate Glucuronosyltransferase Isoform-Dependent Regiospecificity of Glucuronidation of Flavonoids. *Journal of Agricultural and Food Chemistry*, **2012**, 60, 4420-4421	5.7	1
126	Coupling of UDP-glucuronosyltransferases and multidrug resistance-associated proteins is responsible for the intestinal disposition and poor bioavailability of emodin. *Toxicology and Applied Pharmacology*, **2012**, 265, 316-24	4.6	57
125	Systematic studies of sulfation and glucuronidation of 12 flavonoids in the mouse liver S9 fraction reveal both unique and shared positional preferences. *Journal of Agricultural and Food Chemistry*, **2012**, 60, 3223-33	5.7	31
124	Inhibition of P-glycoprotein leads to improved oral bioavailability of compound K, an anticancer metabolite of red ginseng extract produced by gut microflora. *Drug Metabolism and Disposition*, **2012**, 40, 1538-44	4	54
123	Understanding substrate selectivity of human UDP-glucuronosyltransferases through QSAR modeling and analysis of homologous enzymes. *Xenobiotica*, **2012**, 42, 808-20	2	23
122	Accurate prediction of glucuronidation of structurally diverse phenolics by human UGT1A9 using combined experimental and in silico approaches. *Pharmaceutical Research*, **2012**, 29, 1544-61	4.5	14
121	Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling. *Drug Metabolism Reviews*, **2012**, 44, 192-208	7	33
120	Response to Letter to the Editor on Breast Cancer Resistance Protein (ABCG2) Determines Distribution of Genistein Phase II Metabolites: Reevaluation of the Roles of ABCG2 in the Disposition of Genistein *Drug Metabolism and Disposition*, **2012**, 40, 2219.2-2220	4	1
119	Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 1680-5	5.9	54
118	Pharmacokinetics and renal disposition of polymyxin B in an animal model. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 5724-7	5.9	56
117	Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 4625-9	5.9	75
116	Ginsenoside Rb1 directly scavenges hydroxyl radical and hypochlorous acid. *Current Pharmaceutical Design*, **2012**, 18, 6339-47	3.3	35
115	Bioavailability and pharmacokinetics of genistein: mechanistic studies on its ADME. *Anti-Cancer Agents in Medicinal Chemistry*, **2012**, 12, 1264-80	2.2	115
114	UDP-glucuronosyltransferase (UGT) 1A9-overexpressing HeLa cells is an appropriate tool to delineate the kinetic interplay between breast cancer resistance protein (BRCP) and UGT and to rapidly identify the glucuronide substrates of BCRP. *Drug Metabolism and Disposition*, **2012**, 40, 336-45	4	35

113	Breast cancer resistance protein (ABCG2) determines distribution of genistein phase II metabolites: reevaluation of the roles of ABCG2 in the disposition of genistein. *Drug Metabolism and Disposition*, **2012**, 40, 1883-93	4	49
112	Bioavailability challenges associated with development of saponins as therapeutic and chemopreventive agents. *Current Drug Targets*, **2012**, 13, 1885-99	3	36
111	A Useful Microsoft Excel Add-in Program for Modeling Steady-state Enzyme Kinetics. *Pharmaceutica Analytica Acta*, **2012**, 01,	0	4
110	Evaluation of 3,3',4'-trihydroxyflavone and 3,6,4'-trihydroxyflavone (4'-O-glucuronidation) as the in vitro functional markers for hepatic UGT1A1. *Molecular Pharmaceutics*, **2011**, 8, 2379-89	5.6	18
109	Barriers to Oral Bioavailability An Overview **2011**, 1-5		2
108	Physicochemical Characterization of Pharmaceutical Solids **2011**, 7-19		0
107	Solubility of Pharmaceutical Solids **2011**, 21-38		
106	Absorption of Drugs via Passive Diffusion and Carrier-Mediated Pathways **2011**, 63-75		
105	In Vitro In Vivo Correlations of Pharmaceutical Dosage Forms **2011**, 77-89		
104	Drug Metabolism in Gastrointestinal Tract **2011**, 91-109		2
103	Efflux of Drugs via Transporters The Antiabsorption Pathway **2011**, 111-126		2
102	Protein Binding of Drugs **2011**, 145-166		1
101	Liver Drug Metabolism **2011**, 127-144		1
100	Urinary Excretion of Drugs and Drug Reabsorption **2011**, 167-182		1
99	Pharmacokinetic Behaviors of Orally Administered Drugs **2011**, 183-219		2
98	Effects of Food on Drug Absorption **2011**, 221-231		3
97	Drug Drug Interactions and Drug Dietary Chemical Interactions **2011**, 233-251		
96	Anatomical and Physiological Factors Affecting Oral Drug Bioavailability in Rats, Dogs, and Humans **2011**, 253-265		4

95	Organic Anion and Cation Drug Transporters **2011**, 309-327		
94	Gastric Retentive Drug Delivery Systems **2011**, 329-341		1
93	Prodrug Strategies to Enhance Oral Drug Absorption **2011**, 355-369		
92	Oral Delivery of Protein/Peptide Therapeutics **2011**, 371-380		1
91	Interplay between Efflux Transporters and Metabolic Enzymes **2011**, 401-412		1
90	ABC Transporters in Intestinal and Liver Efflux **2011**, 381-400		
89	Regulatory Considerations in Metabolism- and Transporter-Based Drug Interactions **2011**, 413-429		
88	Caco-2 Cell Culture Model for Oral Drug Absorption **2011**, 431-442		2
87	Intestinal Perfusion Methods for Oral Drug Absorptions **2011**, 461-473		
86	MDCK Cells and Other Cell-Culture Models of Oral Drug Absorption **2011**, 443-459		2
85	In vivo Methods for Oral Bioavailability Studies **2011**, 493-503		
84	Liver Perfusion and Primary Hepatocytes for Studying Drug Metabolism and Metabolite Excretion **2011**, 475-491		1
83	Computational and Pharmacoinformatic Approaches to Oral Bioavailability Prediction **2011**, 519-534		2
82	Determination of Regulation of Drug-Metabolizing Enzymes and Transporters **2011**, 505-517		
81	Biological and Physiological Features of the Gastrointestinal Tract Relevant to Oral Drug Absorption **2011**, 51-61		1
80	Drug Transporters and Their Role in Absorption and Disposition of Peptides and Peptide-Based Pharmaceuticals **2011**, 291-308		3
79	Uridine diphosphate glucuronosyltransferase isoform-dependent regiospecificity of glucuronidation of flavonoids. *Journal of Agricultural and Food Chemistry*, **2011**, 59, 7452-64	5.7	24
78	Sulfation of selected mono-hydroxyflavones by sulfotransferases in vitro: a species and gender comparison. *Journal of Pharmacy and Pharmacology*, **2011**, 63, 967-70	4.8	18

77	Role of intestinal hydrolase in the absorption of prenylated flavonoids present in Yinyanghuo. *Molecules*, **2011**, 16, 1336-48	4.8	42
76	Lipid-Based and Self-Emulsifying Oral Drug Delivery Systems **2011**, 343-354		
75	Regioselective glucuronidation of flavonols by six human UGT1A isoforms. *Pharmaceutical Research* , **2011**, 28, 1905-18	4.5	37
74	First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics. *Journal of Pharmaceutical Sciences*, **2011**, 100, 3655-81	3.9	205
73	Poor oral bioavailability of a promising anticancer agent andrographolide is due to extensive metabolism and efflux by P-glycoprotein. *Journal of Pharmaceutical Sciences*, **2011**, 100, 5007-17	3.9	78
72	Sensitive and robust UPLC-MS/MS method to determine the gender-dependent pharmacokinetics in rats of emodin and its glucuronide. *Journal of Pharmaceutical and Biomedical Analysis*, **2011**, 54, 1157-62	3.5	39
71	Validated LC-MS/MS method for the determination of maackiain and its sulfate and glucuronide in blood: application to pharmacokinetic and disposition studies. *Journal of Pharmaceutical and Biomedical Analysis*, **2011**, 55, 288-93	3.5	15
70	Three-dimensional quantitative structure-activity relationship studies on UGT1A9-mediated 3-O-glucuronidation of natural flavonols using a pharmacophore-based comparative molecular field analysis model. *Journal of Pharmacology and Experimental Therapeutics*, **2011**, 336, 403-13	4.7	32
69	Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. *Drug Metabolism and Disposition*, **2011**, 39, 1866-72	4	63
68	In vitro potency of various polymyxin B components. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 4490-1	5.9	31
67	Wiley Series in Drug Discovery and Development **2011**, 541-542		
66	Amino Acid Drug Transporters **2011**, 267-289		
65	In Vitro Dissolution of Pharmaceutical Solids **2011**, 39-49		1
64	Regioselective sulfation and glucuronidation of phenolics: insights into the structural basis. *Current Drug Metabolism*, **2011**, 12, 900-16	3.5	69
63	The pharmacokinetics of raloxifene and its interaction with apigenin in rat. *Molecules*, **2010**, 15, 8478-87	4.8	16
62	Bioavailability challenges associated with development of anti-cancer phenolics. *Mini-Reviews in Medicinal Chemistry*, **2010**, 10, 550-67	3.2	135
61	Highly variable contents of phenolics in St. John's Wort products affect their transport in the human intestinal Caco-2 cell model: pharmaceutical and biopharmaceutical rationale for product standardization. *Journal of Agricultural and Food Chemistry*, **2010**, 58, 6650-9	5.7	20
60	Identification of the position of mono-O-glucuronide of flavones and flavonols by analyzing shift in online UV spectrum (lambdamax) generated from an online diode array detector. *Journal of Agricultural and Food Chemistry*, **2010**, 58, 9384-95	5.7	42

59	Species and gender differences affect the metabolism of emodin via glucuronidation. *AAPS Journal*, **2010**, 12, 424-36	3.7	50
58	Breast cancer resistance protein (BCRP) and sulfotransferases contribute significantly to the disposition of genistein in mouse intestine. *AAPS Journal*, **2010**, 12, 525-36	3.7	53
57	Use of glucuronidation fingerprinting to describe and predict mono- and dihydroxyflavone metabolism by recombinant UGT isoforms and human intestinal and liver microsomes. *Molecular Pharmaceutics*, **2010**, 7, 664-79	5.6	46
56	Biopharmaceutical and pharmacokinetic characterization of matrine as determined by a sensitive and robust UPLC-MS/MS method. *Journal of Pharmaceutical and Biomedical Analysis*, **2010**, 51, 1120-7	3.5	31
55	Use of isoform-specific UGT metabolism to determine and describe rates and profiles of glucuronidation of wogonin and oroxylin A by human liver and intestinal microsomes. *Pharmaceutical Research*, **2010**, 27, 1568-83	4.5	32
54	Simultaneous determination of genistein and its four phase II metabolites in blood by a sensitive and robust UPLC-MS/MS method: Application to an oral bioavailability study of genistein in mice. *Journal of Pharmaceutical and Biomedical Analysis*, **2010**, 53, 81-9	3.5	56
53	Disposition of flavonoids via enteric recycling: UDP-glucuronosyltransferase (UGT) 1As deficiency in Gunn rats is compensated by increases in UGT2Bs activities. *Journal of Pharmacology and Experimental Therapeutics*, **2009**, 329, 1023-31	4.7	36
52	Determination of osthol and its metabolites in a phase I reaction system and the Caco-2 cell model by HPLC-UV and LC-MS/MS. *Journal of Pharmaceutical and Biomedical Analysis*, **2009**, 49, 1226-32	3.5	15
51	Structure and concentration changes affect characterization of UGT isoform-specific metabolism of isoflavones. *Molecular Pharmaceutics*, **2009**, 6, 1466-82	5.6	77
50	Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides. *Molecular Pharmaceutics*, **2009**, 6, 1703-15	5.6	60
49	Oral Absorption Basics **2009**, 263-288		5
48	In vivo pharmacokinetics of hesperidin are affected by treatment with glucosidase-like BglA protein isolated from yeasts. *Journal of Agricultural and Food Chemistry*, **2008**, 56, 5550-7	5.7	32
47	Variable isoflavone content of red clover products affects intestinal disposition of biochanin A, formononetin, genistein, and daidzein. *Journal of Alternative and Complementary Medicine*, **2008**, 14, 287-97	2.4	30
46	Intestinal absorption mechanisms of prenylated flavonoids present in the heat-processed Epimedium koreanum Nakai (Yin Yanghuo). *Pharmaceutical Research*, **2008**, 25, 2190-9	4.5	76
45	Disposition of flavonoids via enteric recycling: enzyme stability affects characterization of prunetin glucuronidation across species, organs, and UGT isoforms. *Molecular Pharmaceutics*, **2007**, 4, 883-94	5.6	32
44	Disposition of flavonoids via enteric recycling: determination of the UDP-glucuronosyltransferase isoforms responsible for the metabolism of flavonoids in intact Caco-2 TC7 cells using siRNA. *Molecular Pharmaceutics*, **2007**, 4, 873-82	5.6	40
43	Natural polyphenol disposition via coupled metabolic pathways. *Expert Opinion on Drug Metabolism and Toxicology*, **2007**, 3, 389-406	5.5	100
42	Commentary: bioavailability of flavonoids and polyphenols: call to arms. *Molecular Pharmaceutics*, **2007**, 4, 803-6	5.6	106

41	Disposition of flavonoids via enteric recycling: structural effects and lack of correlations between in vitro and in situ metabolic properties. *Drug Metabolism and Disposition*, **2006**, 34, 1837-48	4	65
40	Mechanisms responsible for poor oral bioavailability of paeoniflorin: Role of intestinal disposition and interactions with sinomenine. *Pharmaceutical Research*, **2006**, 23, 2768-80	4.5	64
39	Disposition of formononetin via enteric recycling: metabolism and excretion in mouse intestinal perfusion and Caco-2 cell models. *Molecular Pharmaceutics*, **2005**, 2, 319-28	5.6	34
38	Absorption and metabolism of genistein and its five isoflavone analogs in the human intestinal Caco-2 model. *Cancer Chemotherapy and Pharmacology*, **2005**, 55, 159-69	3.5	103
37	Coupling of conjugating enzymes and efflux transporters: impact on bioavailability and drug interactions. *Current Drug Metabolism*, **2005**, 6, 455-68	3.5	93
36	Disposition of flavonoids via recycling: comparison of intestinal versus hepatic disposition. *Drug Metabolism and Disposition*, **2005**, 33, 1777-84	4	59
35	Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. *Drug Metabolism and Disposition*, **2005**, 33, 785-94	4	87
34	Quality, labeling accuracy, and cost comparison of purified soy isoflavonoid products. *Journal of Alternative and Complementary Medicine*, **2004**, 10, 1053-60	2.4	19
33	Disposition of flavonoids via enteric recycling: enzyme-transporter coupling affects metabolism of biochanin A and formononetin and excretion of their phase II conjugates. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 310, 1103-13	4.7	79
32	Disposition mechanisms of raloxifene in the human intestinal Caco-2 model. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 310, 376-85	4.7	59
31	Use of Caco-2 Cell Monolayers to Study Drug Absorption and Metabolism **2004**, 19-35		15
30	Potential beneficial metabolic interactions between tamoxifen and isoflavones via cytochrome P450-mediated pathways in female rat liver microsomes. *Pharmaceutical Research*, **2004**, 21, 2095-104	4.5	43
29	Nucleobase- and p-glycoprotein-mediated transport of AG337 in a Caco-2 cell culture model. *Molecular Pharmaceutics*, **2004**, 1, 194-200	5.6	6
28	In Situ Single-Pass Perfused Rat Intestinal Model for Absorption and Metabolism **2004**, 65-76		17
27	Metabolism of flavonoids via enteric recycling: mechanistic studies of disposition of apigenin in the Caco-2 cell culture model. *Journal of Pharmacology and Experimental Therapeutics*, **2003**, 307, 314-21	4.7	120
26	Functional and molecular characterization of rat intestinal prolidase. *Pediatric Research*, **2003**, 53, 905-14	3.2	13
25	Identification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones. *Drug Metabolism and Disposition*, **2003**, 31, 924-31	4	92
24	Metabolism of flavonoids via enteric recycling: role of intestinal disposition. *Journal of Pharmacology and Experimental Therapeutics*, **2003**, 304, 1228-35	4.7	193

23	Enteric disposition and recycling of flavonoids and ginkgo flavonoids. *Journal of Alternative and Complementary Medicine*, **2003**, 9, 631-40	2.4	57
22	Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. *Journal of Pharmaceutical Sciences*, **2002**, 91, 2511-9	3.9	21
21	Absorption and metabolism of flavonoids in the caco-2 cell culture model and a perused rat intestinal model. *Drug Metabolism and Disposition*, **2002**, 30, 370-7	4	196
20	Analysis of drug transport and metabolism in cell monolayer systems that have been modified by cytochrome P4503A4 cDNA-expression. *European Journal of Pharmaceutical Sciences*, **2000**, 12, 63-8	5.1	23
19	Taurine inhibition of metal-stimulated catecholamine oxidation. *Neurotoxicity Research*, **2000**, 2, 1-15	4.3	14
18	P-glycoprotein and bioavailability-implication of polymorphism. *Clinical Chemistry and Laboratory Medicine*, **2000**, 38, 877-81	5.9	18
17	Lispro insulin: adsorption and stability in selected intravenous devices. *The Diabetes Educator*, **1999**, 25, 237-45	2.5	11
16	Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase. *Pharmaceutical Research*, **1999**, 16, 1352-9	4.5	47
15	Determination of absorption characteristics of AG337, a novel thymidylate synthase inhibitor, using a perfused rat intestinal model. *Journal of Pharmaceutical Sciences*, **1998**, 87, 886-90	3.9	26
14	Development of Caco-2 cells expressing high levels of cDNA-derived cytochrome P4503A4. *Pharmaceutical Research*, **1996**, 13, 1635-41	4.5	54
13	Uptake characteristics of loracarbef and cephalexin in the Caco-2 cell culture model: effects of the proton gradient and possible presence of a distinctive second component. *Journal of Pharmaceutical Sciences*, **1996**, 85, 767-72	3.9	8
12	Mechanisms of transport of quinapril in Caco-2 cell monolayers: comparison with cephalexin. *Pharmaceutical Research*, **1995**, 12, 1120-5	4.5	42
11	Peptide transporter function and prolidase activities in Caco-2 cells: a lack of coordinated expression. *Journal of Drug Targeting*, **1995**, 3, 291-300	5.4	9
10	Mechanisms and kinetics of uptake and efflux of L-methionine in an intestinal epithelial model (Caco-2). *Journal of Nutrition*, **1994**, 124, 1907-16	4.1	39
9	Comparison of the transport characteristics of D- and L-methionine in a human intestinal epithelial model (Caco-2) and in a perfused rat intestinal model. *Pharmaceutical Research*, **1994**, 11, 1771-6	4.5	21
8	Mechanism and kinetics of transcellular transport of a new beta-lactam antibiotic loracarbef across an intestinal epithelial membrane model system (Caco-2). *Pharmaceutical Research*, **1994**, 11, 1405-13	4.5	63
7	Comparison of uptake characteristics of thymidine and zidovudine in a human intestinal epithelial model system. *Journal of Pharmaceutical Sciences*, **1993**, 82, 829-33	3.9	26
6	Transport of a large neutral amino acid in a human intestinal epithelial cell line (Caco-2): uptake and efflux of phenylalanine. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **1992**, 1135, 233-44	4.9	51

5	Utilization of peptide carrier system to improve intestinal absorption: targeting prolidase as a prodrug-converting enzyme. *Journal of Pharmaceutical Sciences*, **1992**, 81, 113-6	3.9	48
4	Pharmaceutical Applications of Cell Culture: An Overview **1991**, 1-14		4
3	Mechanism of L-alpha-methyldopa transport through a monolayer of polarized human intestinal epithelial cells (Caco-2). *Pharmaceutical Research*, **1990**, 7, 1313-9	4.5	62
2	Use of the peptide carrier system to improve the intestinal absorption of L-alpha-methyldopa: carrier kinetics, intestinal permeabilities, and in vitro hydrolysis of dipeptidyl derivatives of L-alpha-methyldopa. *Pharmaceutical Research*, **1989**, 6, 66-70	4.5	75
1	Passive and carrier-mediated intestinal absorption components of captopril. *Journal of Pharmaceutical Sciences*, **1988**, 77, 1007-11	3.9	121